International Assets Investment Management LLC Takes Position in Sanofi (NASDAQ:SNY)

International Assets Investment Management LLC purchased a new stake in Sanofi (NASDAQ:SNY - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 94,586 shares of the company's stock, valued at approximately $4,704,000.

A number of other institutional investors have also recently added to or reduced their stakes in SNY. Cambridge Investment Research Advisors Inc. increased its stake in Sanofi by 16.0% during the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 39,657 shares of the company's stock worth $2,127,000 after buying an additional 5,457 shares in the last quarter. Stratos Wealth Partners LTD. increased its stake in Sanofi by 15.2% during the 3rd quarter. Stratos Wealth Partners LTD. now owns 6,389 shares of the company's stock worth $343,000 after buying an additional 845 shares in the last quarter. Advisor Partners II LLC grew its stake in Sanofi by 28.5% during the 3rd quarter. Advisor Partners II LLC now owns 39,342 shares of the company's stock valued at $2,110,000 after acquiring an additional 8,732 shares in the last quarter. Park Avenue Securities LLC raised its holdings in Sanofi by 3.4% in the 3rd quarter. Park Avenue Securities LLC now owns 64,506 shares of the company's stock valued at $3,460,000 after acquiring an additional 2,135 shares during the last quarter. Finally, CENTRAL TRUST Co lifted its stake in Sanofi by 45.3% in the 3rd quarter. CENTRAL TRUST Co now owns 7,157 shares of the company's stock worth $384,000 after purchasing an additional 2,230 shares in the last quarter. Institutional investors and hedge funds own 10.04% of the company's stock.

Sanofi Trading Down 2.8 %

Shares of NASDAQ:SNY traded down $1.41 during midday trading on Thursday, reaching $48.69. 1,121,985 shares of the company's stock were exchanged, compared to its average volume of 2,003,665. The firm's 50 day simple moving average is $47.99 and its two-hundred day simple moving average is $48.13. Sanofi has a fifty-two week low of $42.63 and a fifty-two week high of $55.72. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.87. The stock has a market cap of $123.17 billion, a price-to-earnings ratio of 25.18, a P/E/G ratio of 1.37 and a beta of 0.61.

Sanofi Increases Dividend

The business also recently declared an annual dividend, which will be paid on Thursday, June 6th. Stockholders of record on Friday, May 10th will be paid a $1.478 dividend. This represents a dividend yield of 2.98%. This is an increase from Sanofi's previous annual dividend of $1.38. The ex-dividend date is Thursday, May 9th. Sanofi's payout ratio is 69.35%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on SNY shares. TheStreet lowered Sanofi from a "b" rating to a "c" rating in a research report on Friday, February 9th. Morgan Stanley initiated coverage on Sanofi in a research note on Tuesday, January 23rd. They issued an "equal weight" rating and a $55.00 target price for the company. Finally, StockNews.com cut shares of Sanofi from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, February 27th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $55.00.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.